2022 Revenues ($USD) : $100,330,000,000.00
2022 R&D spend : $11,428,000,000.00
2022 Number of Employees : 83,000
Fiscal Year End : 12/31/22
Leader : CEO Dr. Albert Bourla

In 2022, Pfizer's revenue surpassed $100 billion for the first time. Compared with 2021 revenue figures, Pfizer achieved 30% operational growth. While the COVID-19 antiviral Paxlovid and the vaccine Comirnaty drove a substantial share of profits, the company was on a growth trajectory without them. Excluding those two therapies, operational revenue growth was 2%. As demand for COVID-19 products continues to cool, however, the company is unlikely to be able to sustain its momentum. Some analysts expect sales to decline as much as a third in 2023. Pfizer continues to bank on M&A deals to help fuel its growth prospects. Recent acquisitions from the company include its $6.7 billion acquisition of Arena Pharmaceuticals, $11.6 billion buy of Biohaven and its $5.4 billion purchase of Global Blood Therapeutics. —BB